Forecasts of explosive AI progress predict that what researchers call recursive self-improvement is on the horizon.  But a new study suggests that it might take a while for us to get there. The ...

On Tuesday, the AI company Recursive Superintelligence announced a $410 million compute deal with Amazon Web Services. The company, which emerged from stealth in May with $650 million in funding, is ...

The US AI research company Anthropic has become known for building powerful AI models while simultaneously warning about their dangers. “We are not there yet, and recursive self-improvement is not ...

Recursion Pharmaceuticals operates as a TechBio company, using its proprietary Recursion OS to automate biological experiments and analyze them with artificial intelligence. The company generates vast ...

Choosing between Recursion Pharmaceuticals(NASDAQ:RXRX) and Summit Therapeutics(NASDAQ:SMMT) requires weighing the broad potential of artificial intelligence against the specific clinical prospects of ...

Recursion Pharmaceuticals leverages an artificial intelligence platform to decode biology and automate the drug discovery process. Summit Therapeutics is focused on its lead oncology candidate, ...

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...

The companies at the frontier of artificial intelligence should be ready to slow down, one of the fastest-moving among them says. Anthropic, the maker of the Claude chatbot, has claimed AI systems may ...

RSI is also defined as an “AI system capable of fully autonomously designing and developing its own successor,” per Anthropic’s blog post. “We are not there yet, and recursive self-improvement is not ...

As drug discovery moves from trial-and-error to digital simulation, choosing between Recursion Pharmaceuticals(NASDAQ:RXRX) and Schrödinger(NASDAQ:SDGR) depends on ...